The Cooper Companies, Inc. (COO)
- Previous Close
79.51 - Open
78.71 - Bid 72.22 x 200
- Ask 85.05 x 200
- Day's Range
77.59 - 78.98 - 52 Week Range
69.81 - 112.38 - Volume
2,177,269 - Avg. Volume
2,017,711 - Market Cap (intraday)
15.899B - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
38.02 - EPS (TTM)
2.07 - Earnings Date May 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 26, 2023
- 1y Target Est
105.55
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia; and spherical lense, including lenses that correct near and farsightedness in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including paragard contraceptive intrauterine devices; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
www.coopercos.com16,000
Full Time Employees
October 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: COO
View More
Performance Overview: COO
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COO
View MoreValuation Measures
Market Cap
15.74B
Enterprise Value
18.18B
Trailing P/E
38.02
Forward P/E
19.68
PEG Ratio (5yr expected)
1.34
Price/Sales (ttm)
4.02
Price/Book (mrq)
1.94
Enterprise Value/Revenue
4.63
Enterprise Value/EBITDA
16.59
Financial Highlights
Profitability and Income Statement
Profit Margin
10.57%
Return on Assets (ttm)
3.80%
Return on Equity (ttm)
5.25%
Revenue (ttm)
3.93B
Net Income Avi to Common (ttm)
415.4M
Diluted EPS (ttm)
2.07
Balance Sheet and Cash Flow
Total Cash (mrq)
100.9M
Total Debt/Equity (mrq)
31.25%
Levered Free Cash Flow (ttm)
243M
Research Analysis: COO
View MoreResearch Reports: COO
View MoreRaising target price to $82.00
COOPER COS INC/THE has an Investment Rating of HOLD; a target price of $82.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRating decreased to a HOLD
COOPER COS INC/THE has an Investment Rating of HOLD; a target price of $75.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetTariffs Raise Near-Term Uncertainty for Vision Care Firms, Especially for Struggling Ones
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
RatingPrice TargetTariffs Raise Near-Term Uncertainty for Vision Care Firms, Especially for Struggling Ones
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
RatingPrice Target